Effects of soluble human leukocyte antigen G on the standardized treatment of hepatitis C patients

doi:10.12092/j.issn.1009-2501.2018.07.014

Abstract

Abstract:

AIM: To investigate the effect of soluble human leukocyte antigen G (sHLA-G) on the efficacy of pegylated interferon combined with ribavirin in the treatment of chronic hepatitis C (CHC). METHODS: A total of 63 CHC patients from October 2013 to October 2015 were enrolled. The genotype of hepatitis C virus (HCV), HCV RNA and sHLA-G were detected by gene chip, RT-PCR and ELISA method accordingly. All patients received a subcutaneous injection of pegylated interferon combined with oral ribavirin. The factors affecting the sustained virological response (SVR) were observed and analyzed. RESULTS: The proportion of female and non-genotype 1 in SVR group was significantly higher than that in non-sustained virological response (NSVR) group (female:70.59% vs.44.83%, χ²=4.285; non-genotype 1:82.76% vs.55.88%, χ²=5.217, P<0.05); other baseline indexes presented no significant difference (P>0.05). The level of plasma sHLA-G before treatment in NSVR group was significantly higher than that in SVR group［1.85(1.49-16.00) ng/L vs.1.53(1.36-2.80) ng/L; U=329.00, P<0.05］. After multivariable logistic regression analysis, sHLA-G and HCV genotypes were the independent influencing factors associated with the outcome of treatment with Exp(B)(95% CI) were 0.922(0.868-0.978) and 14.204(1.898-106.289), respectively. CONCLUSION: sHLA-G exhibits an important effect on the standardized treatment of hepatitis C patients, and patients with low sHLA-G level are more likely to achieve a sustained virological response.

Key words: chronic hepatitis C, ribavirin, treatment, pegylated interferon, soluble human leukocyte antigen G

CLC Number:

R749

ZHOU Yong, YING Li, XU Jiajia, DING Shixiong, HU Airong, GAO Guosheng. Effects of soluble human leukocyte antigen G on the standardized treatment of hepatitis C patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 809-813.

References

［1］Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence［J］. Hepatology, 2013, 57: 1333-1342.

［2］Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection［J］. World J Gastroenterol, 2013, 19: 7896-7909.

［3］中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版)［J］. 临床肝胆病杂志, 2015, 31(12): 1961-1979.

［4］丁世雄, 周文红, 胡爱荣, 等. 宁波地区丙型肝炎病毒基因分型检测［J］. 中国卫生检验杂志, 2011, 21(10): 2453-2454.

［5］Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection［J］. N Engl J Med, 2009, 360: 1839-1850.

［6］游春芳, 周利民, 邓薇. 基因1b型慢性丙型肝炎患者血清铁蛋白水平与聚乙二醇干扰素抗病毒疗效的关系［J］. 临床肝胆病杂志, 2017, 33(9): 1713-1716.

［7］Kwon JH, Bae SH. Current status and clinical course of hepatitis C virus in Korea［J］. Korean J Gastroenterol, 2008, 51: 360-367．

［8］李小宁, 杨正海, 李静. 不同基因型丙型肝炎病毒非结构蛋白NS3对端粒酶活性的研究［J］. 中国临床药理学与治疗学, 2015, 20(2): 128-131.

［9］徐严, 斯庆图娜拉, 郎轶宣, 等. 聚乙二醇干扰素α-2a个体化抗病毒治疗慢性丙型肝炎的疗效［J］. 中华传染病杂志, 2012, 30(3): 165-169.

［10］刘娜, 徐光华, 李春霞, 等. 影响丙型肝炎抗病毒疗效因素的研究进展［J］. 医学综述, 2015, 8(17): 3082-3084.

［11］崔燕平, 管珊, 王金燕, 等. 聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎的疗效分析［J］. 国际流行病学传染病学杂志, 2016, 43(5): 348-350.

［12］贾因棠, 段晓红, 杨中鑫, 等. IL-28B、IFNL4基因多态性与慢性丙型肝炎患者聚乙二醇干扰素联合利巴韦林抗病毒疗效相关性的研究［J］. 中华肝脏病杂志, 2017, 25(7): 529-532.

［13］陈新月, 尚佳, 杨瑞锋, 等. 难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究［J］. 中华肝脏病杂志, 2015, 23(6): 412-417．

［14］周明琴, 蒋素文, 胡爱荣, 等. 慢性丙型肝炎患者标准化治疗应答的相关因素分析［J］. 中华全科医学, 2016, 14(2): 240-242.

［15］窦晓光. 影响丙型肝炎初治患者标准化治疗疗效的相关因素及对策［J］. 中华肝脏病杂志, 2013, 21(6): 406-407.

［16］Dai CY, Chuang WL, Hsieh MY, et al. Human leukocyte antigen alleles and the response to PEGylated interferon/ribavirin therapy in chronic hepatitis C patients［J］. Antiviral Res, 2010, 85(2): 396-402.

［17］Fitzmaurice K, Hurst J, Dring M, et al. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection ［J］. Gut, 2015, 64(5): 813-819.

［18］胡彬, 颜卫华. 人类白细胞抗原-G与肝脏疾病研究进展［J］. 中华传染病杂志, 2017, 35(3): 187-189.

［19］de Oliveira Crispim JC, Silva TG, Souto FJ, et al. Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infection［J］. Hum Immunol, 2012, 73(3): 258-262.

［20］Amiot L, Vu N, Rauch M, et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis ［J］. J Hepatol, 2014, 60(2): 245-252.

［21］Weng PJ, Fu YM, Ding SX, et al. Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection［J］. Hum Immunol, 2011,72: 406-411.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[3]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[4]	WANG Juan, LIU Weiying, YE Yucai, FU Wenli, ZHANG Sha, LI Leping. Research progress of norepinephrine reuptake inhibitor combined with antimuscarinic in the treatment of obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 714-720.
[5]	LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao. Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
[6]	TAO Yijia, YANG Chun, LIU Cunming . Progress in clinical application of topical anesthesia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 594-600.
[7]	ZHANG Li, LIN Xingyao, SHANG Yun, WANG Qiang. Progress on the pathological mechanism and treatment of frostbite [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 347-354.
[8]	DANG Yangbin, LIANG Yuxin, WANG Tiancheng. Research progress on the related treatment of progressive myoclonic epilepsy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1184-1194.
[9]	JIA Tao, TENG Jinliang. New narcotic analgesics: esketamine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 834-840.
[10]	DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708.
[11]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.
[12]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[13]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[14]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[15]	ZHOU Shiqin, LUO Yali, ZHOU Wen, Qi Xiaofeng, XIAO Mengyong. Molecular mechanism and treatment of pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1133-1147.